KyungDong Pharm home
Prescription Medicines

Setoride Tab.

Product Category
Peptic ulcer medication
Active Ingredients
Leaf 95% ethanol soft extract (20→1)
Appearance
Green oval film-coated tablets
Reimbursement Code
648103570
View Regulatory Information on the MFDS Portal ↗
1. Composition and Strength
1 tablet
- Active ingredient: Leaf 95% ethanol soft extract (20→1) (in-house specification) ----- 60mg (0.48~1.44mg as eupatillin, 0.15~0.45mg as jasocidin)
- Additives (tar color aluminum lake): Blue No. 1, Blue No. 2, Yellow No. 4, Yellow No. 5
- Additives (animal-derived ingredients): Lactose hydrate (cow, milk)
- Other additives: Calcium silicate, microcrystalline cellulose, magnesium stearate, Opagloss 2 Clear (97W19196), Opadry Green (200F610000), Croscarmellose Na
Trium, talc, polysorbate 80, polyethylene glycol 6000, hypromellose

2. Effectiveness
1. Improvement of gastric mucosal lesions (erosion, bleeding, redness, edema) of the following diseases: acute gastritis, chronic gastritis
2. Prevention of gastritis caused by administration of nonsteroidal anti-inflammatory drugs (NSAIDs)

3. Dosage and dosage
As a 95% ethanol soft extract, 60 mg at a time is administered orally three times a day.

4. Precautions for use
1. Do not administer to the following patients.
Because this drug contains lactose, it should not be administered to patients with genetic problems such as galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption.
2. Administer with caution to the following patients.
1) Patients with blood clots (cerebral thrombosis, myocardial infarction, venous thrombosis, etc.)
2) Patients with consumptive coagulopathy
3) Patients with serious disorders in the liver, kidneys, heart, lungs, blood, etc.
4) Patients with or history of drug allergy symptoms (rash, fever, itching, etc.)
5) Since this medicine contains Yellow No. 4 (tartrazine), administer with caution to patients who are hypersensitive to this ingredient or have a history of allergy.
6) This medicine contains Yellow No. 5 (Sunset Yellow FCF), so administer with caution to patients who are hypersensitive to this ingredient or have a history of allergy.
3. Adverse reactions
1) The adverse reactions by manifestation site reported among 386 people who participated in the phase 3 clinical trial for acute and chronic gastritis in Korea are as follows.
(1) Digestive system: Occasionally nausea (0.78%), loss of appetite (0.52%), diarrhea (0.52%), vomiting (0.26%), heartburn (0.26%), and epigastric pain (0.26%) occurred.
(2) Mental nervous system: Dizziness (0.26%) and headache (0.26%) occasionally occurred.
(3) Skin: Occasionally rash (0.26%) and itching (0.26%) occurred.
(4) Liver and biliary system: Sometimes ALT elevation (0.26%) occurred.
2) The adverse reactions by site of occurrence reported among 266 people who participated in a phase 3 clinical trial for the prevention of gastritis caused by the administration of non-steroidal anti-inflammatory drugs (NSAIDs) in Korea are as follows. For reference, since this clinical trial was conducted with simultaneous administration of a non-steroidal anti-inflammatory analgesic and this drug, it is not clear whether the following adverse reactions are caused by the non-steroidal anti-inflammatory analgesic or this drug. Additionally, adverse reactions do not necessarily have a causal relationship with the investigational drug.
(1) Cardiovascular system: Sometimes palpitations appeared.
(2) Digestive system: Very often abdominal distension, epigastric pain, heartburn, nausea, and diarrhea appeared. Occasionally, lower abdominal pain, constipation, indigestion, burping, gastrointestinal hypermotility, gastroesophageal reflux, vomiting, and hunger appeared.
(3) Liver and biliary tract: Frequently increased ALT and occasionally increased bilirubin in the blood.
(4) Metabolism and nutritional system: Occasionally, an increase in appetite was observed.
(5) Nervous system: Sometimes headaches appeared.
(6) Mental system: Sometimes insomnia appeared.
(7) Genitourinary system: Difficulty urinating occasionally occurred.
(8) Respiratory system: Nasopharyngitis sometimes appeared.
(9) Others: Occasionally, an increase in LDH in the blood was observed.
3) As a result of the post-marketing use results survey conducted on 3,416 cases of domestic acute and chronic gastritis patients, adverse reactions were reported in 0.18% (6 cases/3,416 cases), and adverse reactions with a causal relationship with the drug were reported in 0.15% (5 cases/3,416 cases) (loss of appetite, nausea, indigestion, abdominal pain, etc. were reported in 0.03% (1 case each)). Additionally, an unexpected adverse reaction for which the causal relationship with this drug could not be determined was facial edema (0.03% (1 case)).
4) As a result of a post-marketing use survey conducted on 429 arthritis patients who received this drug for the purpose of preventing gastritis caused by domestic NSAID administration, adverse reactions were reported at 2.10% (9 cases/429 cases), and adverse reactions with a causal relationship with the drug were 0.93% (4 cases/429 cases) (upper abdominal pain 0.70% (3 cases), nausea) It was reported as 0.23% (1 case).
4. General precautions
1) This drug has not been studied for use in patients with peptic ulcers (excluding scars) and reflux esophagitis, in patients with gastritis and gastric ulcers caused by NSAID administration, in patients with a history of gastrectomy, or in patients with duodenal ulcers.
2) In clinical trials, this drug has been administered for up to 2 weeks for acute and chronic gastritis. If symptoms do not improve after 2 weeks of administration, discontinue administration and consult a pharmacist or doctor.
5. Interaction
No studies have been conducted on drug interactions with this drug.
6. Administration to pregnant and lactating women
1) Since the safety of this drug for administration during pregnancy has not been established, it should be administered to pregnant women or women who may be pregnant only when the therapeutic benefits are judged to outweigh the risks.
2) Since it is not known whether this drug passes into breast milk, it should be administered to nursing mothers only when the therapeutic benefits are judged to outweigh the risks.
7. Influence of clinical test values
1) When this drug was administered at a daily dose of 180 mg for 2 weeks, AST values tended to decrease significantly, but were mostly within the normal range. Occasionally, abnormal increases in ALT values and rare cases of abnormal increases in LDH values were reported.
2) When this drug was administered at a daily dose of 360 mg for 2 weeks, red blood cells, hemoglobin, neutrophils, total protein, ALP, and AST values decreased significantly, and lymphocytes tended to increase significantly, but most were within the normal range.
3) In a domestic phase 3 clinical trial for the prevention of gastritis caused by non-steroidal anti-inflammatory drugs, when this drug was administered at a daily dose of 180 mg for 4 weeks, hemoglobin and neutrophil values tended to decrease significantly, and ALT, albumin, and LDH values significantly increased, but returned to the normal range.
8. Storage and handling precautions
1) Store out of reach of children.
2) Avoid direct sunlight and store tightly in a cool place with as little moisture as possible.
3) Be careful not to put it in another container as it may cause an accident or is undesirable in terms of maintaining quality.

5. How to save
Airtight container, stored at room temperature (1~30℃)

6. Packaging unit
30 tablets/bottle, 300 tablets/bottle

7. Period of use
36 months from date of manufacture